NCT06827457

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci120 in Healthy Adult Participants in China

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.

Conditions

• Autoimmune Disease

Interventions

Type	Name	Description
DRUG	GenSci120	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2025-02-20
• Primary completion: 2025-11-27
• Completion: 2025-12-16
• First posted: 2025-02-14
• Last updated: 2025-12-24

Locations

1 site across 1 country: China